111In-Fab displayed a clear difference in tumour uptake between the moderate- and high-CD44v6-expressing tumours, ranging between 1.5 to 2 times higher for the high-CD44v6-expressing A431 tumours (calculated for each individual mouse) throughout the study. This evidence concerns the gene FANCB and neoplasm.